All News
ILD in Juvenile Dermatomyositis: Moving Toward Better Outcomes
Juvenile dermatomyositis (JDM) is typically recognized for its striking skin rashes, vasculopathy, and muscle inflammation. Less visible, but equally significant, is lung involvement.
Read Article
German survey of 124 AOSD pts - Dz duration 7 yrs (Dx delay 2 yrs), 2/3 on biologics, 84% responding, 81% inactive by CRP. MDs report 35% of pts Sx-free. More Patients report Persistent Sxs LBP (39.5%), fatigue/weakness (39%), & joint inflammation (27%). https://t.co/2FGUPrhB8H
Dr. John Cush RheumNow ( View Tweet)
Phase 3 RCT Cannabis sativa DKJ127 (VER-1) in 820 chronic low back pain (cLBP) pts. Primary endpt at wk 12 showed pain reduction of −1.9 NRS VER-01 vs −0.6 PBO (P < 0.001). Pain further decreased to −2.9 w/ 6 mos OL Rx. VER-1 was well tolerated. No addiction https://t.co/IeCV8tU2WR
Dr. John Cush RheumNow ( View Tweet)
Systematic review of obesity management meds - 56 RCTs (60,307 pts). All OMMs were better at total weight loss than PBO (P < 0.0001), >10% semaglutide & tirzepatide (both effective at NIDDM CHF). Semaglutide effective reducing pain in knee osteoarthritis https://t.co/nbdZfBDukE
Dr. John Cush RheumNow ( View Tweet)
Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis
FDA announced yesterday that guselkumab (Tremfya) is approved for use in pediatric patients moderate to severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA) in children six years and older https://t.co/GHjCgqHaJC
Dr. John Cush RheumNow ( View Tweet)
What is IPAF?
Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD.
https://t.co/ThU4pq27MU https://t.co/AOa5PALJst
Links:
Dr. John Cush RheumNow ( View Tweet)
🆕 ILD (Part III): clinical practice focus 🔬 Diagnostic challenges 🧑⚕️ Case-based learning 📈 Evidence & outcomes 🌍 Global perspectives ⬇️ Download & learn more: https://t.co/WhpVzAfPDD Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/4CL9mX9D6Y
Dr. John Cush RheumNow ( View Tweet)
There is no consensus on flare definition in PSA. Review of 12 #PsA studies shows flare prevalence ranged 7% to 10%, w/ incidence was 22–23%. Over 12 mos, current patient-reported flare = 10%, physician-reported flare = 7% https://t.co/2LKlnaMSyv https://t.co/0TYXiZGsSc
Dr. John Cush RheumNow ( View Tweet)
Small 38 pt. RCT found that 16-wks of Mediterranean diet signif improved psoriasis PASI scores. Intervention grp had better PASI change at week 16 (−3.4 vs 0), PASI 75, and reducted hemoglobin A1c. Diet as adjunctive Rx in PsO!! https://t.co/oJnaAA8LMm https://t.co/AXxI8FWQqU
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 137 pts w/ Usual interstitial pneumonia (UIP) w/ myositis Abs testing. 11% MSA+. & more like to have autoimmune Dz, +ANA, +RF. MSA negativity predicted by these 4: neg RF, ANA <1:320, no hypergammaglobulinemia, no Raynaud's - specificity 100%, sensitivity https://t.co/JAca1fpwZT
Dr. John Cush RheumNow ( View Tweet)
Detection, Monitoring & Management of Autoimmune ILD
The American Journal of Managed Care has reviewed the approach to patients with ILD; a significant cause of morbidity and mortality in those with SARDs, including RA, SSc, and IIM.
https://t.co/xtRfLNyZA6 https://t.co/S9JFlMd9CN
Dr. John Cush RheumNow ( View Tweet)
Axial involvement in PsA (axPsA)? study of 581 PsA pts (mean 45 yrs) found 31% w/ SpA-SI joint (SIJ) abnormalities on MRI (MRI-axPsA). MRI-axPsA pts had BM edema(69%), erosions (68%), fat lesions (58%). ~45% w/ Xrays, 29% met Xray mNY criteria for AS (38% +MRI). +MRI assoc w/ https://t.co/MRbs8G3MWq
Dr. John Cush RheumNow ( View Tweet)
Study of 246 axSpA (nraxSpA 82, r-axSpA 164) w/ Sxduration 26 yrs. axSpA had more comorbid Dz (^CCI) esp for uveitis (28 vs 1%), IBD (10 v 1%), PsO (10 v 3%)], CVD (7 v 3%), FM (12 v 3%). BUT NO DIFF between r-axSp & nraxSpA for comorbidities https://t.co/0ERLt083yq https://t.co/65x02ZFKTb
Links:
Dr. John Cush RheumNow ( View Tweet)
How Does Your Garden Grow (9.26.2025)
Dr. Jack Cush reviews the news and journal articles from RheumNow. Pool therapy, Fibrosis, NSIE's and what's best for knee OA.
https://t.co/JCf9u8Wd4O https://t.co/g0xLmEMLbS
Dr. John Cush RheumNow ( View Tweet)
QD clinics on ILD - lessons from the Clinic #3
QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign ILD QD Clinic #3 ILD QD Clinic: Application of the ACR CHEST Guidelines to Two Cases ILD QD Clinic: Progressive RA-ILD Management https://t.co/oYZf9KT9JF
Dr. John Cush RheumNow ( View Tweet)
What is IPAF?
Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD.
https://t.co/ZEexaqoeLK https://t.co/p3Yfv2IkE2
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Stick or twist (when not to change treatment)
Dr. Richard Conway, Dublin, discusses a case about when not to change treatment, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/9yQwWTnEtU https://t.co/7k0cSsaPqN
Dr. John Cush RheumNow ( View Tweet)
TREG EULAR 2025 - Review of SLE & Autoimmune Rheumatic Diseases (AIRD) https://t.co/8Em6Dp0oL5 via @YouTube
Dr. John Cush RheumNow ( View Tweet)
Interstitial lung abnormalities (ILA) are found in 7% of Gen. population, most of whom are asymptomatic, but some will progress to ILD, IPF,and increased risk of lung cancer, etc. Finding incidental ILD appropriate screening monitoring, based on risk factors is indicated. https://t.co/kQbhxTAVTm
Dr. John Cush RheumNow ( View Tweet)
HLA-B27: still the most important genetic factor in axSpA susceptibility, but has lower frequency African American, South American & Middle Eastern pop. B27 discerns clinical subsets of SpA and PsA, particularly acute anterior uveitis or axSpA with psoriasis, https://t.co/S4s0NvuwNY
Dr. John Cush RheumNow ( View Tweet)
